OrbiMed Advisors CAI Position
Active3-Fund ConvergenceOrbiMed Advisors increased their position in Caris Life Sciences, Inc. (CAI) in Q4 2025, holding $84.1M worth of shares across 3,116,011 shares.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
CAI is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
Full company profile →Short Interest
5.2%
3.3 days to cover
OrbiMed Advisors CAI Position History
Frequently Asked Questions
Does OrbiMed Advisors own CAI?
Yes. As of Q4 2025, OrbiMed Advisors holds 3,116,011 shares of Caris Life Sciences, Inc. (CAI) valued at $84.1M. This data comes from their SEC 13F filing.
How many hedge funds own CAI?
3 specialist biotech hedge funds currently hold CAI, including Perceptive Advisors, Rock Springs Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy CAI?
OrbiMed Advisors's position in CAI was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's CAI position increasing or decreasing?
OrbiMed Advisors increased their CAI position in the most recent quarter, adding 81,153 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CAICompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →